Treatment of Relapsed Acute Myeloid Leukemia.
Thol F, Ganser A.
Curr Treat Options Oncol. 2020 Jun 29;21(8):66. doi: 10.1007/s11864-020-00765-5.
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study.
Rheingold SR, Bhojwani D, Ji L, Xu X, Devidas M, Kairalla JA, Shago M, Heerema NA, Carroll AJ, Breidenbach H, Borowitz M, Wood BL, Angiolillo AL, Asselin BL, Bowman WP, Brown P, Dreyer ZE, Dunsmore KP, Hilden JM, Larsen E, Maloney K, Matloub Y, Mattano LA, Winter SS, Gore L, Winick NJ, Carroll WL, Hunger SP, Raetz EA, Loh ML.
Leukemia. 2024 Nov;38(11):2382-2394. doi: 10.1038/s41375-024-02395-4. Epub 2024 Sep 11.
Multiple myeloma with high-risk cytogenetics and its treatment approach.
Hanamura I.
Int J Hematol. 2022 Jun;115(6):762-777. doi: 10.1007/s12185-022-03353-5. Epub 2022 May 9.
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, Bahlis N.
Blood Adv. 2020 Dec 8;4(23):5988-5999. doi: 10.1182/bloodadvances.2020002827.
Cytogenetic evolution predicts a poor prognosis in acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
Li R, Wang Z, Zhang Y, Guo M, Ni X, Chen J, Chen L, Gao L, Gong S, Tang G, Yang J, Wang J.
Ann Hematol. 2023 Jan;102(1):89-97. doi: 10.1007/s00277-022-05061-w. Epub 2022 Dec 21.
A revised prognostic model for patients with acute myeloid leukemia and first relapse.
van der Maas NG, Breems D, Klerk CPW, Pabst T, Gradowska P, Thomas A, Biemond BJ, Kuball J, Van Elssen CHMJ, Visser O, Vekemans MC, Graux C, Maertens J, Knapper S, Dennis M, Freeman S, Thomas I, Beverloo HB, Huls G, Craddock C, Valk PJM, Vyas P, Russell N, Ossenkoppele G, Löwenberg B, Cornelissen JJ, Versluis J.
Blood Adv. 2025 Aug 12;9(15):3853-3864. doi: 10.1182/bloodadvances.2025015797.
Acute myelogenous leukemia.
Aquino VM.
Curr Probl Pediatr Adolesc Health Care. 2002 Feb;32(2):50-8. doi: 10.1067/mps.2002.121791.
Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Lin F, Kirkland MA, van Rhee FV, Chase A, Coulthard S, Bungey J, Goldman JM, Cross NC.
Bone Marrow Transplant. 1996 Dec;18(6):1147-52.
FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology.
McCormick SR, McCormick MJ, Grutkoski PS, Ducker GS, Banerji N, Higgins RR, Mendiola JR, Reinartz JJ.
Arch Pathol Lab Med. 2010 Aug;134(8):1143-51. doi: 10.5858/2009-0292-OA.1.
Acute promyelocytic leukemia at time of relapse commonly demonstrates cytogenetic evidence of clonal evolution and variability in blast immunophenotypic features.
Dimov ND, Medeiros LJ, Ravandi F, Bueso-Ramos CE.
Am J Clin Pathol. 2010 Mar;133(3):484-90. doi: 10.1309/AJCPJ7K0AWMBHMAI.
